Investigational drug · Phase 2
efocipegtrutide
Also called: HM15211
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NASH - Nonalcoholic Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "efocipegtrutide"
First trial start
2020
Jul 31, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "efocipegtrutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- NASH - Nonalcoholic Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "efocipegtrutide" as an intervention, largest first.
- Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT04505436 · 215 participants · Start Jul 31, 2020 · Primary completion Jun 26, 2026
Drug: HM15211; Placebo of HM15211 · For: NASH - Nonalcoholic Steatohepatitis
Sites: Huntsville, Alabama; Chandler, Arizona; Chula Vista, California · 60 sites in all
Hanmi Pharmaceutical Company LimitedIndustry
NCT03744182 · 66 participants · Start Nov 1, 2018 · Primary completion Mar 18, 2020
Drug: HM15211; Placebo of HM15211 · For: NAFLD
Sites: Chula Vista, California
Hanmi Pharmaceutical Company LimitedIndustry
NCT03374241 · 41 participants · Start Apr 4, 2018 · Primary completion Sep 14, 2018
Drug: HM15211 or Placebo · For: Obesity
Sites: Chula Vista, California
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.
Bhat S, Fernandez CJ, Lakshmi V, et al. · World J Cardiol 2025
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.
Bailey CJ, Flatt PR, Conlon JM · Peptides 2025
- A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.
Abdelmalek MF, Suzuki A, Sanchez W, et al. · Contemp Clin Trials 2023
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
Jepsen MM, Christensen MB · Expert Opin Emerg Drugs 2021
Also in development for NASH - Nonalcoholic Steatohepatitis
- EfruxiferminPhase 33 trials
Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH
- IVA337LanifibranorPhase 31 trial
Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis
- SNP-610Phase 21 trial
Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.